Laurel Wealth Advisors (North Carolina)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-1,120
Closed -$14K – 633
2022
Q1
$14K Hold
1,120
– – ﹤0.01% 379
2021
Q4
$26K Hold
1,120
– – 0.01% 321
2021
Q3
$25K Hold
1,120
– – 0.01% 322
2021
Q2
$15K Buy
+1,120
New +$14.3K ﹤0.01% 411

Other funds holding AUPH

Laurel Wealth Advisors (North Carolina)'s AUPH Position: Q2 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2022, closing a stake of 1,120 shares — an estimated $14K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in AUPH in Q2 2021 and held it in 4 quarters. The position peaked at $26K in Q4 2021. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Aurinia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 1,120 Aurinia Pharmaceuticals shares in Q2 2022, an estimated $14K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Aurinia Pharmaceuticals position peaked at $26K in Q4 2021.
  • 199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2022, filed 12 Aug 2022.